GLP1R and type 2 diabetes mellitus: Due to the short plasma half-life of native GLP-1, several GLP-1RAs have been developed for the treatment of T2DM [2], for example, short-acting analogs such as lixisenatide (half-life ~3 h), intermediate-acting analogs such as liraglutide (half-life 13–15 h), and long-acting analogs such as semaglutide (half-life 1 week) [3].